Literature DB >> 22524199

Inflammasome polymorphisms confer susceptibility to sporadic malignant melanoma.

Deepti Verma1, Cecilia Bivik, Ensieh Farahani, Ingrid Synnerstad, Mats Fredrikson, Charlotta Enerbäck, Inger Rosdahl, Peter Söderkvist.   

Abstract

Genetic variants of NLRP3 and NLRP1 are known to modulate levels of pro-inflammatory cytokine interleukin (IL)-1β. The purpose of this study was to investigate the association of NLRP3/NLRP1 polymorphisms with susceptibility and clinical features of malignant melanoma in a Swedish case-control study. Common variants in NLRP3/NLRP1 were investigated in sporadic malignant melanoma patients and healthy controls followed by analysis using logistic regression. NLRP3 variant (rs35829419) was significantly more common in male patients than in controls (OR, 2.22; CI, 1.27-3.86). Upon stratification, significant association with nodular melanoma was observed (OR, 2.89; CI, 1.33-6.30), which intensified in male patients (OR 4.03, CI 1.40-11.59). The NLRP1 variant (rs12150220) was significantly more common in fair-skinned female patients (OR, 1.85; CI, 1.04-3.33) and showed strong associations with nodular melanoma (OR, 6.03; CI, 1.33-25). Our data suggest that NLRP3/NLRP1 polymorphisms are associated with melanoma susceptibility; these findings warrant validation in other independent populations.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22524199     DOI: 10.1111/j.1755-148X.2012.01008.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  44 in total

1.  Autolytic proteolysis within the function to find domain (FIIND) is required for NLRP1 inflammasome activity.

Authors:  Joshua N Finger; John D Lich; Lauren C Dare; Michael N Cook; Kristin K Brown; Chaya Duraiswami; John Bertin; John J Bertin; Peter J Gough
Journal:  J Biol Chem       Date:  2012-06-04       Impact factor: 5.157

Review 2.  Inflammasomes in Myeloid Cells: Warriors Within.

Authors:  Sushmita Jha; W June Brickey; Jenny Pan-Yun Ting
Journal:  Microbiol Spectr       Date:  2017-01

3.  Genetic polymorphisms of IL-18 rs1946518 and IL-1β rs16944 are associated with prognosis and survival of acute myeloid leukemia.

Authors:  Hong Wang; Mingqiang Hua; Shukang Wang; Jie Yu; Chen Chen; Xueyun Zhao; Chen Zhang; Chaoqin Zhong; Ruiqing Wang; Na He; Ming Hou; Daoxin Ma
Journal:  Inflamm Res       Date:  2016-12-07       Impact factor: 4.575

Review 4.  NLRP3 inflammasome in cancer and metabolic diseases.

Authors:  Bhesh Raj Sharma; Thirumala-Devi Kanneganti
Journal:  Nat Immunol       Date:  2021-03-11       Impact factor: 25.606

Review 5.  Inflammasomes and Cancer.

Authors:  Rajendra Karki; Si Ming Man; Thirumala-Devi Kanneganti
Journal:  Cancer Immunol Res       Date:  2017-01-16       Impact factor: 11.151

Review 6.  The Emerging Role of Inflammasomes as Central Mediators in Inflammatory Bladder Pathology.

Authors:  Brian M Inouye; Francis M Hughes; Stephanie J Sexton; J Todd Purves
Journal:  Curr Urol       Date:  2017-12-30

7.  Interactome-wide analysis identifies end-binding protein 1 as a crucial component for the speck-like particle formation of activated absence in melanoma 2 (AIM2) inflammasomes.

Authors:  Li-Jie Wang; Chia-Wei Hsu; Chiu-Chin Chen; Ying Liang; Lih-Chyang Chen; David M Ojcius; Ngan-Ming Tsang; Chuen Hsueh; Chih-Ching Wu; Yu-Sun Chang
Journal:  Mol Cell Proteomics       Date:  2012-08-06       Impact factor: 5.911

8.  MiR-22 sustains NLRP3 expression and attenuates H. pylori-induced gastric carcinogenesis.

Authors:  S Li; X Liang; L Ma; L Shen; T Li; L Zheng; A Sun; W Shang; C Chen; W Zhao; J Jia
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

Review 9.  Differential role of the NLRP3 inflammasome in infection and tumorigenesis.

Authors:  Sarang Tartey; Thirumala-Devi Kanneganti
Journal:  Immunology       Date:  2019-02-14       Impact factor: 7.397

Review 10.  Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer.

Authors:  Sonia Missiroli; Mariasole Perrone; Caterina Boncompagni; Chiara Borghi; Alberto Campagnaro; Francesco Marchetti; Gabriele Anania; Pantaleo Greco; Francesco Fiorica; Paolo Pinton; Carlotta Giorgi
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.